Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
Drugs and Vaccines for Developing Countries
1 June 2011
Forthcoming in the Oxford Handbook on the Economics of the Biopharmaceutical Industry, this paper describes the context of the problem of access to medicines in developing…
Measuring Value with Pharmacoeconomics
26 May 2011
In forthcoming chapter in the Oxford Handbook on the Economics of the Biopharmaceutical Industry, experts in the field outline the evolution of cost-effectiveness analysis (CEA) through…
Incorporating Multiple Criteria in HTA
19 April 2011
This OHE publication is intended to inform and stimulate debate about the way different sorts of evidence and considerations are taken into account in decisions about…
New: Antimicrobial Drug Incentives
6 April 2011
Antimicrobial resistance (AMR) is becoming a major global public health threat. In this new OHE Research Paper, the authors identify barriers to the development of new…
Value-Based Pricing: OHE Comments
23 March 2011
In December 2010, the UK Department of Health released a consultation document to elicit comments on ‘proposals for a new value-based system of pricing medicines which…
Differential Pricing – A Win-Win Solution?
2 March 2011
Summarised in this post is a just-released OHE Occasional Paper that examines the potentially positive impact of differential pricing in Europe and the overall negative effects…
New: Priority Review Vouchers and Innovation
17 February 2011
This OHE Seminar Briefing recounts a presentation by Prof Henry Grabowski on US Priority Review Vouchers, intended to provide an incentive for the development of drugs…
Update: Value-Based Pricing in the UK
11 January 2011
Value-based pricing for new medicines, proposed as part of UK health care reform, would create a QALY-plus approach for drugs approved starting 1 January 2014. For…
Health and the Use of Medicines in Primary Care in Wales
1 November 2011
In this, report commissioned by the ABPI in Wales, OHE Consulting examines the use of medicines in primary care in Wales since 2000 compared to the…